**Table S1. Comparisons of adverse events and health conditions between vaccine doses among children and adolescents aged 5 to 17 years following Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, December 13, 2021 to June 20, 2022**

| Events | Age group (5–11 y) | | Age group (12–17 y) | | p-value<sup)a</sup> | | p-value<sup>b</sup> |
|---|---|---|---|---|---|---|---|
| | Dose 1 (n = 1,025) | Dose 2 (n = 541) | | Dose 1 (n = 10,389) | Dose 2 (n = 3,147) | |
| Local adverse events | 336 (32.8) | 148 (27.4) | 0.027 | 5,009 (48.2) | 1,672 (53.1) | <0.001 |
| Pain | 309 (30.1) | 133 (24.6) | 0.020 | 4,612 (44.4) | 1,546 (49.1) | <0.001 |
| Redness | 17 (1.7) | 11 (2.0) | 0.595 | 234 (2.3) | 108 (3.4) | <0.001 |
| Swelling | 58 (5.7) | 29 (5.4) | 0.807 | 973 (9.4) | 371 (11.8) | <0.001 |
| Itching | 30 (2.9) | 11 (2.0) | 0.292 | 276 (2.7) | 107 (3.4) | 0.028 |
| Urticaria | 5 (0.5) | 1 (0.2) | 0.595 | 51 (0.5) | 14 (0.4) | 0.744 |
| Others | 42 (4.1) | 25 (4.6) | 0.626 | 592 (5.7) | 195 (6.2) | 0.296 |
| Systemic adverse events | 275 (26.8) | 121 (22.4) | 0.053 | 4,351 (41.9) | 1,651 (52.5) | <0.001 |
| Fever | 94 (9.2) | 48 (8.9) | 0.845 | 797 (7.7) | 723 (23.0) | <0.001 |
| Chills | 55 (5.4) | 21 (3.9) | 0.194 | 596 (5.7) | 452 (14.4) | <0.001 |
| Headache | 97 (9.5) | 40 (7.4) | 0.168 | 1,717 (16.5) | 999 (31.7) | <0.001 |
| Joint pain | 15 (1.5) | 3 (0.6) | 0.109 | 266 (2.6) | 181 (5.8) | <0.001 |
| Myalgia | 132 (12.9) | 48 (8.9) | 0.018 | 2,474 (23.8) | 865 (27.5) | <0.001 |
| Fatigue or tiredness | 95 (9.3) | 45 (8.3) | 0.531 | 2,091 (20.1) | 892 (28.3) | <0.001 |
| Nausea | 37 (3.6) | 14 (2.6) | 0.279 | 680 (6.5) | 322 (10.2) | <0.001 |
| Vomiting | 13 (1.3) | 5 (0.9) | 0.544 | 47 (0.5) | 28 (0.9) | 0.004 |
| Diarrhea | 16 (1.6) | 6 (1.1) | 0.470 | 224 (2.2) | 81 (2.6) | 0.167 |
| Abdominal pain | 20 (2.0) | 10 (1.8) | 0.888 | 379 (3.6) | 171 (5.4) | <0.001 |
| Rash | 3 (0.3) | 0 | 0.556 | 35 (0.3) | 16 (0.5) | 0.169 |
| Armpit tenderness | 30 (2.9) | 20 (3.7) | 0.410 | 412 (4.0) | 327 (10.4) | <0.001 |
| Chest pain<sup>b</sup> | 8 (0.8) | 6 (1.1) | 0.575 | - | - | - |
| Heart palpitations<sup>b</sup> | 4 (0.4) | 1 (0.2) | 0.665 | - | - | - |
| Others | 42 (4.1) | 19 (3.5) | 0.569 | 523 (5.0) | 180 (5.7) | 0.129 |
| Unable to perform normal daily activities | 95 (9.3) | 39 (7.2) | 0.166 | 1,052 (10.1) | 613 (19.5) | <0.001 |
| Visits to medical facilities | 35 (3.4) | 20 (3.7) | 0.773 | 116 (1.1) | 44 (1.4) | 0.200 |
| Emergency department visit | 0 | 0 | - | 18 (0.2) | 7 (0.2) | 0.574 |
| Hospitalization | 0 | 1 (0.2) | 0.346 | 2 (0) | 0 | 1.000 |
| Clinic visit | 35 (3.4) | 19 (3.5) | 0.920 | 100 (1.0) | 39 (1.2) | 0.177 |

Data are presented as n (%): the percentage of respondents who reported adverse events and health conditions at least once during days 0 to 7 post-vaccination.

COVID-19, coronavirus disease 2019.

<sup>a</sup>Events reported by respondents who completed at least 1 text message-based survey on days 0 to 7. Respondents were able to report multiple adverse events on each day.

<sup>b</sup>These were additionally investigated only for children aged 5 to 11 years.

<sup>c</sup>Chi-square or Fisher exact test as appropriate.